Alejandro Forner
Impact in
- Hepatology top 0.01%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 0.5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
- Hepatology 131
- Hepatocellular Carcinoma Treatment and Prognosis 127
- Hepatitis C virus research 5
- Surgery 28
- Cholangiocarcinoma and Gallbladder Cancer Studies 26
- Co-authors
- Jordi Bruix (82 shared papers)Josep Maria Llovet (16 shared papers)María Reig (64 shared papers)Vincenzo Mazzaferro (4 shared papers)Jean‐Luc Raoul (7 shared papers)Peter R. Galle (3 shared papers)Fabio Piscaglia (2 shared papers)Valérie Vilgrain (1 shared paper)
- Journals
- Journal of Hepatology (38 papers)Liver International (18 papers)Hepatology (10 papers)The Lancet Oncology (6 papers)Cancers (6 papers)
- Partner nations
- SpainItalyUnited States
In The Last Decade
Alejandro Forner
165 papers receiving 43.8k citations
Alejandro Forner's Hit Papers
Peers
Comparison fields: 5 of 147
- Hepatology 30.3k
- Cancer Research 2.6k
- Oncology 3.1k
- Radiology, Nuclear Medicine and Imaging 2.3k
- Surgery 3.3k
Countries citing papers authored by Alejandro Forner
This map shows the geographic impact of Alejandro Forner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro Forner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro Forner more than expected).
Fields of papers citing papers by Alejandro Forner
This network shows the impact of papers produced by Alejandro Forner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro Forner. The network helps show where Alejandro Forner may publish in the future.
Co-authors
The 25 scholars most cited alongside Alejandro Forner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 175 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sorafenib in Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2008 | 11101 |
| 2 | EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma Hit paper breakdown → | 2018 | 7945 |
| 3 | Hepatocellular carcinoma Hit paper breakdown → | 2018 | 4521 |
| 4 | Hepatocellular carcinoma Hit paper breakdown → | 2012 | 3649 |
| 5 | BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update Hit paper breakdown → | 2021 | 3068 |
| 6 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management Hit paper breakdown → | 2020 | 1787 |
| 7 | Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis Hit paper breakdown → | 2008 | 1715 |
| 8 | Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects Hit paper breakdown → | 2010 | 934 |
| 9 | Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hit paper breakdown → | 2007 | 842 |
| 10 | Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics Hit paper breakdown → | 2006 | 755 |
| 11 | Management of HCC Hit paper breakdown → | 2012 | 530 |
| 12 | Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence Hit paper breakdown → | 2018 | 483 |
| 13 | Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization Hit paper breakdown → | 2010 | 454 |
| 14 | Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design Hit paper breakdown → | 2012 | 404 |
| 15 | Treatment of intermediate-stage hepatocellular carcinoma Hit paper breakdown → | 2014 | 390 |
| 16 | 2008 | 365 | |
| 17 | 2010 | 261 | |
| 18 | Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry Hit paper breakdown → | 2022 | 256 |
| 19 | 2020 | 255 | |
| 20 | 2009 | 247 |
About Alejandro Forner
Alejandro Forner is a scholar working on Hepatology, Surgery, Radiology, Nuclear Medicine and Imaging, Oncology and Dermatology, having authored 175 papers that have together received 44.6k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (127 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (26 papers), MRI in cancer diagnosis (7 papers), Hepatitis C virus research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Liver Disease Diagnosis and Treatment (4 papers), Chemotherapy-related skin toxicity (4 papers) and Artificial Intelligence in Healthcare and Education (3 papers). The work is most often cited by research in Hepatology (30.3k citations), Cancer Research (2.6k citations), Oncology (3.1k citations), Radiology, Nuclear Medicine and Imaging (2.3k citations) and Surgery (3.3k citations). Alejandro Forner has collaborated with scholars based in Spain, Italy and United States. Frequent co-authors include Jordi Bruix, Josep Maria Llovet, María Reig, Vincenzo Mazzaferro, Jean‐Luc Raoul, Peter R. Galle, Fabio Piscaglia, Valérie Vilgrain, Peter Schirmacher and Carmen Ayuso. Their work appears in journals such as Journal of Hepatology, Liver International, Hepatology, The Lancet Oncology and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.